Public trial registry of the CCC-Munich

Trial ATALANTE_AGO OVAR 2.30

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ATALANTE_AGO OVAR 2.30
World
Full title
:

A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab

World
Responsible organization
:
Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Gynecological tumor
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo,Zielgerichtet - Therapieart: palliativ

Participants
Function Prename Surname Organization
World Responsible contact Holger Bronger Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany Magnifier